Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Appointed CFO Quarterly results Appointed director
|
GALECTIN THERAPEUTICS INC (GALT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
11/13/2018 |
8-K
| Quarterly results |
08/14/2018 |
8-K
| Quarterly results |
05/11/2018 |
8-K
| Quarterly results |
11/07/2017 |
8-K
| Quarterly results |
08/18/2017 |
8-K/A
| Quarterly results |
08/14/2017 |
8-K
| Quarterly results |
05/15/2017 |
8-K
| Form 8-K - Current report |
11/08/2016 |
8-K
| Form 8-K - Current report |
08/09/2016 |
8-K
| Quarterly results |
05/10/2016 |
8-K
| Quarterly results |
11/12/2013 |
8-K
| Quarterly results |
08/14/2013 |
8-K
| Quarterly results |
11/09/2012 |
8-K
| Quarterly results |
08/10/2012 |
8-K
| Quarterly results |
05/11/2012 |
8-K
| Quarterly results |
08/14/2009 |
8-K
| Quarterly results |
05/15/2009 |
8-K
| Form 8-K -- Current report |
11/07/2008 |
8-K
| Quarterly results |
08/08/2008 |
8-K
| Quarterly results |
05/20/2008 |
8-K
| Quarterly results |
08/10/2007 |
8-K
| Quarterly results |
11/13/2006 |
8-K
| Quarterly results |
11/23/2004 |
8-K
| Quarterly results
Docs:
|
"Pro-Pharmaceuticals Reports Third Quarter Results",
"Dr. David Platt Gratified with Arbitrator's Decision: Continues to Control Prosecution of Modified Pectin Patent Applications Patent Applications Relate to GCS-100, GlycoGenesys' Core Technology Decision Has No Bearing on Dr. Platt's Lawsuit Against GlycoGenesys or Their Counterclaims Against Dr. Platt & Pro-Pharmaceuticals Newton, MA, November 12, 2004 - David Platt, Ph.D., CEO & President of Pro-Pharmaceuticals, Inc. , today said he was gratified by the Arbitrator's decision to allow him to continue to control the prosecution of his patent applications that relate to the modified pectin technology that he developed and licensed to GlycoGenesys, Inc. in 1994. The Arbitrator ruled that Dr. Platt will continue to retain the power of attorney to control prosecution of his U.S. Patent Applica...",
"Pro-Pharmaceuticals “Sets the Record Straight” Regarding Misleading Statements Made by GlycoGenesys in News Releases Newton, MA, November 18, 2004 - Pro-Pharmaceuticals, Inc. , a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, is “Setting the Record Straight” regarding misleading statements made by GlycoGenesys, Inc. in two news releases issued on November 11. The news releases relate to an Arbitration decision between David Platt, Ph.D., President & CEO of Pro-Pharmaceuticals and GlycoGenesys, and pending Litigation between GlycoGenesys, Dr. Platt and Pro-Pharmaceuticals." |
|
|
|